uniQure
uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.
Leadership
Matt Kapusta
CEO
Financial Performance
Funding
Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2012
7.8M USD
Series A
2013
79.25M USD
Series B
2014
91.8M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Venture Capital
United Kingdom
Corporation
Italy
Government Agency
Switzerland
Venture Capital
Netherlands
Venture Capital
Netherlands
Investment Bank
Germany
*More data available at: [CB Insights] [CrunchBase] [PitchBook]
Related
News
News